



CEO and Managing Director Remuneration

Perth, Australia & Malta – 29 January 2019 – Neurotech International Limited (ASX: NTI) (**Neurotech** or **the Company**) is pleased to provide remuneration details for Chief Executive Officer (**CEO**) and Managing Director, Mr Peter Griffiths.

As a core part of key leadership of the Company, Mr Griffiths was appointed in November 2018 and will be focused on executing on the new strategic direction of the Company, further detailed in the investor presentation “Strategic Review and Capital Raise” also released today.

The key highlights of Mr Griffiths’ remuneration comprise:

- Initial fee (base remuneration) of €13,333 per month (€160,000 per year);
- This base remuneration and any cash bonuses paid are subject to the quantum of revenue achieved by the Company in each financial year; and
- Subject to shareholder approval, the award of:
 - 6,500,000 Options, exercisable at A\$0.0589 per Share (**Tranche 1 Options**); and
 - The number of Options equivalent to 4% of the total Shares on issue at 30 June 2019, with exercise price determined by reference to the performance of the Company’s share price to 30 June 2019 or the issue price of Shares in a capital raising, as relevant (**Tranche 2 Options**).

Both tranches of options will vest over the period to 31 December 2020, with vesting subject to continuation of Mr Griffiths’ appointment and conduct.

The Agreement commenced on 1 December 2018 and is for an initial term of 12 months following which it will continue, until terminated in accordance with its terms with six months’ notice. A full summary of the terms and conditions of the Mr Griffiths’ appointment and the terms of the proposed options are included at sections of 9.7 and 9.8 of the Company’s prospectus for a renounceable pro-rata rights issue to be lodged with ASIC and released to ASX today.

-ends-

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 225 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism.

Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated delta band brain activity.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420